Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy.

Purpose: Lutetium-177 Prostate-specific membrane antigen (Lu-PSMA) radioligand therapy is EMA-approved for metastatic castration resistant prostate cancer (mCRPC) after androgen receptor pathway inhibition (ARPI) and taxan-based chemotherapy. However, its effect in taxan-naïve patients is under curr...

Full description

Bibliographic Details

Published in:	European Journal of Nuclear Medicine & Molecular Imaging Vol. 52; no. 6; pp. 2015 - 2023
Main Authors:	Wenzel, Mike, Hoeh, Benedikt, Siech, Carolin, Koll, Florestan, Humke, Clara, Groener, Daniel, Steuber, Thomas, Graefen, Markus, Maurer, Tobias, Banek, Severine, Chun, Felix K. H., Mandel, Philipp
Format:	Journal Article
Published:	Springer Nature May2025
Online Access:	View this record in EBSCOhost